Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon Provigil Cost Of Goods To Decrease From 22% Of Sales To 7%

Executive Summary

Cephalon expects to reduce its cost of goods associated with the narcolepsy drug Provigil from 22% of sales to 7% of sales following its acquisition of the French company Lafon

You may also be interested in...



Cephalon Sales Force Expansion Funding Vehicle Dissolved In Wake Of Enron

Cephalon's investment vehicle to fund expanded sales efforts for Provigil (modafinil) and Gabitril (tiagabine) has been dissolved due to investor skepticism following the collapse of Enron

Cephalon Sales Force Expansion Funding Vehicle Dissolved In Wake Of Enron

Cephalon's investment vehicle to fund expanded sales efforts for Provigil (modafinil) and Gabitril (tiagabine) has been dissolved due to investor skepticism following the collapse of Enron

Provigil Revamped Marketing Campaign To Launch After FDA Cites Promotions

Cephalon plans to proceed with a new marketing program for Provigil (modafinil) in February after receiving a letter from FDA objecting to many of its current promotional materials for the narcolepsy drug

UsernamePublicRestriction

Register

OM006764

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel